Valuation: Beacon Pharmaceuticals PLC

Market Cap 25.48B 206M 179M 167M 153M 289M 19.63B 292M 1.96B 767M 9.82B 775M 758M 32.55B P/E 2024
68.2x
P/E 2025 25.8x
Enterprise Value 35.44B 287M 248M 232M 213M 403M 27.3B 407M 2.72B 1.07B 13.66B 1.08B 1.05B 45.28B EV / Sales 2024
4.25x
EV / Sales 2025 2.74x
Free-Float
36.94%
Yield 2024
1.3%
Yield 2025 1.98%
1 week-1.27%
Current month+0.09%
1 month-2.34%
3 months+5.85%
6 months+1.78%
Current year+3.82%
1 week 108
Extreme 108
110.2
1 month 107
Extreme 107
117.9
Current year 96
Extreme 96
117.9
1 year 96
Extreme 96
147.5
3 years 92.4
Extreme 92.4
288.9
5 years 92.4
Extreme 92.4
393
10 years 16
Extreme 16
393
Manager TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - -
Chief Administrative Officer - -
Director TitleAgeSince
Chairman 67 -
Director/Board Member 42 -
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-1.27%-4.06%-55.67% 203M
+4.86%-4.16%+52.13%+160.26% 995B
+1.04%-3.43%+50.60%+52.38% 614B
+0.98%-6.46%+24.85%+66.66% 431B
+1.96%-0.87%+43.02%+37.60% 353B
-0.11%-4.56%+31.59%+39.73% 293B
+2.52%-6.99%+8.08%+10.32% 245B
+4.57%+3.75%+35.07%+67.64% 210B
-4.32%-12.25%-5.97%-44.56% 210B
-2.58%-1.91%+15.06%+67.46% 168B
Average +0.75%-4.48%+25.04%+40.18% 351.84B
Weighted average by Cap. +0.72%-5.89%+36.58%+75.03%

Financials

2024 2025
Net sales 10.7B 86.67M 75.03M 69.95M 64.37M 122M 8.24B 123M 822M 322M 4.12B 326M 318M 13.67B 12.54B 102M 87.94M 81.98M 75.44M 142M 9.66B 144M 963M 378M 4.83B 381M 373M 16.03B
Net income 521M 4.22M 3.65M 3.41M 3.13M 5.92M 401M 5.98M 40.01M 15.69M 201M 15.85M 15.5M 666M 947M 7.67M 6.64M 6.19M 5.69M 10.75M 729M 10.86M 72.68M 28.5M 365M 28.79M 28.16M 1.21B
Net Debt 10B 80.97M 70.09M 65.34M 60.13M 114M 7.7B 115M 768M 301M 3.85B 304M 297M 12.77B 9.96B 80.69M 69.85M 65.12M 59.93M 113M 7.67B 114M 765M 300M 3.84B 303M 296M 12.73B
Logo Beacon Pharmaceuticals PLC
Beacon Pharmaceuticals PLC is a Bangladesh-based pharmaceutical company. The Company is engaged in the manufacturing and marketing of pharmaceutical finished formulation products and lifesaving Intravenous (I.V) fluids, active pharmaceuticals ingredients, biotech products, and genetic engineering products which it sells in the local markets as well as the international markets. The Company also provides contract and toll manufacturing services. Its products are focused on various drugs, such as anticancer, cardiovascular, gastrointestinal, antibiotics, anti-coagulants, protein supplements, muscle relaxant, antihistamine, analgesics, and non-steroidal anti-inflammatory drugs (NSAIDS), among others. The Company's product categories include general, oncology, anti-viral, and biotech. Its products include Tagrix 80, Afanix 40, Ibrutix, Lenvanix 4, Palbonix, Crizonix, Sunitix, Wedica, Tafecta, Hernix, Obetix, Ribotix, among others.
Employees
4,771
Date Price Change Volume
04/08/26 BDT 108.60 0.00% 183,925
03/08/26 BDT 108.60 +0.09% 155,831
02/08/26 BDT 108.50 0.00% 106,204
30/07/26 BDT 108.50 +0.28% 197,132
29/07/26 BDT 108.20 -1.64% 394,745
  1. Stock Market
  2. Stocks
  3. BEACONPHAR Stock